Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients

Inclusion criteria: * Male or female patients with mild to moderate Alzheimer's disease, aged between 50 and 85 years inclusive * Meets criteria for probable Alzheimer's of the National Institute of Neurologic and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association * Mini-mental state examination (MMSE) * In reasonable and stable health state for Alzheimer's patients of this age and stage of disease as assessed by a comprehensive clinical assessment * Magnetic resonance imaging consistent with Alzheimer's disease, not indicating any other cause for dementia symptoms than Alzheimer's disease * Rosen Modified Hachinski Ischemic score * If on symptomatic treatment for Alzheimer's disease (acetylcholinesterase inhibitors or/and memantine), must be stable in the last 30 days before screening Exclusion criteria: * Clinically significant neurological disease other than Alzheimer's disease * Had a major psychiatric disorder * Had a history of stroke, seizures, brain neoplasms, brain surgery, or any cerebrovascular disorder (including transient ischemic attack) * History or presence of severe, uncontrolled and/or unstable angiopathy or vasculitis. * History or presence of clinically relevant cardiac disease. * Currently taking anticonvulsants, anti-Parkinsonians, antipsychotics, anticoagulants or narcotic drugs, recent immunosuppressive or cancer chemotherapy drugs, or cognitive enhancers. Concomitant therapies that are allowed if given at a stable dose for at least 30 days before screening are: acetylcholinesterase inhibitors and/or memantine; antidepressants of the class of selective serotonin reuptake inhibitors (no tricyclics); acetyl salicylic acid (ASA) at a dose ≤ 160 mg/day; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.